Castle Biosciences (CSTL) Cash from Investing Activities (2018 - 2026)

Castle Biosciences has reported Cash from Investing Activities for 9 years, with the latest figure at -$16.0 million in Q2 2026.

• Quarterly Cash from Investing Activities rose 43.75% year-over-year to -$16.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$51.3 million (up 14.21% YoY) and the FY2025 annual result came in at -$60.4 million, down 20.4% from the prior year.
• Cash from Investing Activities improved to -$16.0 million in Q2 2026 per CSTL's latest filing, from -$25.8 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $16.6 million in Q1 2023 and troughed at -$134.2 million in Q3 2022.
• A 5-year average of -$18.6 million and a median of -$15.7 million in 2023 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2022 and 2023: Cash from Investing Activities sank 14434.13% in 2022, then soared 4225.37% in 2023.
• Over 5 years, Cash from Investing Activities stood at -$4.5 million in 2022, then slumped by 71.17% to -$7.7 million in 2023, then soared by 175.21% to $5.8 million in 2024, then jumped by 53.05% to $8.8 million in 2025, then slumped by 280.76% to -$16.0 million in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered -$16.0 million, -$25.8 million, and $8.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.